Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptor isoforms A and B in endometriotic cells
article
OA: closed
CC0
⤵ 23 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
Dienogest down-regulates CYP19A1, inflammatory factors, and neuroangiogenesis factors in endometriotic cells via progesterone receptor isoforms A and B.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (49)
- Advances in the management of endometriosis: an update for clinicians via openalex
- Chronic Pelvic Pain in Endometriosis: An Overview via openalex
- Dienogest via openalex
- Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system via openalex
- Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis via openalex
- Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture via openalex
- Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β via openalex
- Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells via openalex
- Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
- Endometrial stromal progesterone receptor-A/progesterone receptor-B ratio: no difference between women with and without endometriosis via openalex
- Endometriosis: the pathophysiology as an estrogen-dependent disease via openalex
- Estrogen Receptor-β, Estrogen Receptor-α, and Progesterone Resistance in Endometriosis via openalex
- Expression of Inducible Microsomal Prostaglandin E Synthase in Local Lesions of Endometriosis Patients via openalex
- Immunohistochemical characterization of endometriosis-associated smooth muscle cells in human peritoneal endometriotic lesions via openalex
- Inflammatory Status Influences Aromatase and Steroid Receptor Expression in Endometriosis via openalex
- Long-term use of progestogens – effects on endometriosis, adenomyosis and myomas via openalex
- Progesterone and progestational compounds attenuate tumor necrosis factor alpha–induced interleukin-8 production via nuclear factor kappaB inactivation in endometriotic stromal cells via openalex
- Progesterone Receptor Isoform A But Not B Is Expressed in Endometriosis via openalex
- Promoter Methylation Regulates Estrogen Receptor 2 in Human Endometrium and Endometriosis1 via openalex
- Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via openalex
- The elusive and controversial roles of estrogen and progesterone receptors in human endometriosis. via openalex
- W2039274017 via openalex
- W2045458073 via openalex
- W2038266542 via openalex
- W2032416959 via openalex
- W2068397002 via openalex
- W2025620374 via openalex
- W2022658482 via openalex
- W2080251208 via openalex
- W2021942629 via openalex
- W2011025558 via openalex
- W2093775195 via openalex
- W2101417341 via openalex
- W2110802986 via openalex
- W2010391061 via openalex
- W2129503523 via openalex
- W2134753968 via openalex
- W2002512356 via openalex
- W2134863579 via openalex
- W2002351432 via openalex
- W2001963326 via openalex
- W2159228424 via openalex
- W1981024564 via openalex
- W1840935595 via openalex
- W1598886839 via openalex
- W6633520577 via openalex
- W6656140975 via openalex
- W6658221620 via openalex
Cited by (23)
- Hormonal Dysregulation and Neuroinflammation in Endometriosis: Convergent Druggable Pathways 2026
- WITHDRAWN: Effects of Deinorgestrel Treatment of Endometriosis on Ovarian Function, Inflammatory Factors, and Pregnancy Rate in Patients 2025
- Diminished Ovarian Reserve in Endometriosis: Insights from In Vitro, In Vivo, and Human Studies—A Systematic Review 2023
- Neurotrophins and Their Receptors, Novel Therapeutic Targets for Pelvic Pain in Endometriosis, Are Coordinately Regulated by IL-1β via the JNK Signaling Pathway 2023
- Dienogest May Reduce Estradiol- and Inflammatory Cytokine-Induced Cell Viability and Proliferation and Inhibit the Pathogenesis of Endometriosis: A Cell Culture- and Mouse Model-Based Study 2022
- Segmented in vitro fertilization and frozen embryo transfer in dienogest-treated patient with adenomyosis: A case report and lierature review 2022
- Potential Therapeutic Options and Perspectives for Alleviation of Endometrial Estrogen Dominance and Progesterone Resistance in Endometriosis 2021
- Empirical and long-term therapy for endometriosis-associated pelvic pain 2021
- Pharmacology of Endometriosis 2021
- Ovarian reserve after three-step laparoscopic surgery for endometriomas utilizing dienogest: a non-randomized prospective pilot study. 2020
- Ovarian reserve after three-step laparoscopic surgery for endometriomas utilizing dienogest: a non-randomized prospective pilot study 2020
- A progestin isn’t a progestin: dienogest for endometriosis as a blueprint for future research – Review as a contribution for discussion - 2020
- Three-Dimensional Biofabrication Models of Endometriosis and the Endometriotic Microenvironment 2020
- Ovarian reserve after three‐step laparoscopic surgery for endometriomas utilizing dienogest: A pilot study 2020
- Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure 2020
- Endometriosis: current challenges in modeling a multifactorial disease of unknown etiology 2020
- Three-Dimensional Biofabrication Models of Endometriosis and the Endometriotic Microenvironment 2020
- Cyclooxygenase-2 in Endometriosis 2019
- Is endometriosis a benign disease? Modern controversial aspects of endometriosis-associated ovarian tumors 2016
- Drospirenone reduces inflammatory cytokines, vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) expression in human endometriotic stromal cells 2016
- Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis 2016
- Does dienogest influence the inflammatory response of endometriotic cells? A systematic review 2015
- Treatment of pain associated with deep endometriosis: alternatives and evidence 2015
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:18:04.362919+00:00
License: CC0
· commercial use OK